ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate / issue of duplicate share certificate under Regulation 39(3) of the SEBI (LODR) Regulations, 2015
Zydus Lifescience Q1 PAT seen up 58.6% YoY to Rs 839.1 cr: Nirmal Bang
Net Sales are expected to increase by 24 percent Y-o-Y (up 0.8 percent Q-o-Q) to Rs 5,050.3 crore, according to Nirmal Bang.
Zydus Lifesciences gains on USFDA's all-clear for Ahmedabad unit
The company has also received final approval from the United States Food and Drug Administration for Oxcarbazepine tablets. Oxcarbazepine is used to treat epilepsy ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication with regard to Notice of 29th Annual General Meeting, information on e-voting and record date ZYDUS WELLNESS LTD.-$ - 531335 - Business Responsibility and Sustainability Reporting (BRSR)
Business Responsibility Report for the Financial Year 2022-2023 ZYDUS WELLNESS LTD.-$ - 531335 - 29Th Annual General Meeting Scheduled To Be Held On August 3, 2023
29th Annual General Meeting to be held on August 3, 2023 ZYDUS WELLNESS LTD.-$ - 531335 - Reg. 34 (1) Annual Report.
Annual Report for the Financial Year 2022-2023 ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on June 30, 2023 ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper cutting dated July 1, 2023 with regard to Notice and other information on 29th Annual General Meeting of the Company
Buy Zydus Lifesciences; target of Rs 663: Sharekhan
Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 663 in its research report dated June 28, 2023.